Previous New Releases from NCBI BookshelfInebilizumab (Uplizna): CADTH Reimbursement Recommendation: Indication: As monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive [Internet].Inebilizumab (Uplizna): CADTH Reimbursement Recommendation: Indication: As monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive [Internet].
